Ochsner J. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. In the acute stage of gadolinium exposure, patients complained of central and peripheral pain, headache, bone pain, and skin thickening. It is only slightly malleable and is a ductile rare-earth element.Gadolinium reacts with atmospheric oxygen or moisture slowly to form a black coating. HHS Risk of Nephrogenic Systemic Fibrosis after Exposure to Newer Gadolinium Agents [Internet]. It must be chelated when used in the body. “Therefore, we cannot completely rule out that gadolinium deposition may have an impact on disease progression or clinical outcome,” said Zivadinov. This site needs JavaScript to work properly. (2020). 58, No. 2018 May;69(2):136-150. doi: 10.1016/j.carj.2017.11.002. Gadolinium-based contrast agents (GBCAs) have an excellent safety profile. Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Can Assoc Radiol J. “Gadolinium deposition disease” is what Chuck Norris’ wife Gena claims to have developed after undergoing three contrast-enhanced MRIs in a single week to evaluate her rheumatoid arthritis. ©RSNA, 2019. USA.gov. Study finds no clinical impact of gadolinium deposition in brains of MS patients. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Gadolinium deposition disease (GDD) has been proposed as the name for a newly described, not yet widely accepted, condition of gadolinium (Gd) toxicity. Epub 2020 Jun 18. Although shrouded in controversy as to its pathophysiologic mechanism, modifiable risk factors, and even existence as a disease in its own right, GDD has grown salient in the public eye—a fact not lost on personal injury attorneys. 2010 Jan;51(1):39-44. doi: 10.1007/s00108-009-2408-9. (1.4). Lersy F, Boulouis G, Clément O, Desal H, Anxionnat R, Berge J, Boutet C, Kazémi A, Pyatigorskaya N, Lecler A, Saleme S, Edjlali-Goujon M, Kerleroux B, Ben Salem D, Kremer S, Cotton F. J Neuroradiol. Published July 10, 2019. “Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents”, from Neuroradiology medical journal (First Online: February 2, 2019) — Abstract; For more about Gadolinium Deposition Disease (GDD) in patients, which is a form of gadolinium toxicity and sometimes called, instead, Gadolinium Storage Condition, see our … 2020 Apr;17(4):546-550. doi: 10.1016/j.jacr.2019.11.009. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Concerns around gadolinium-based contrast agents (GBCAs) include both gadolinium deposition disease, a controversial term that refers to the retention of small amounts of gadolinium in the body long after MRI scans take place, and nephrogenic systemic fibrosis (NSF), a debilitating disease that occurs in individuals with compromised kidney function. Rofo. Clipboard, Search History, and several other advanced features are temporarily unavailable. 2019. Used in as many as 30% of MRIs performed in the United States, GBCAs have generally been associated with low rates of adverse events. NIH Two known brain surgeons faced with a mountain of questions from patients about gadolinium safety wrote an article for AAP news about convincing these concerned individuals that gadolinium is safe. Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology. GDD or Gadolinium toxicity may include bone, skin and tissue pain, “brain fog” and/or progressive thickening of the skin. USA.gov. Published by Elsevier Inc. All rights reserved. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. [Nephrogenic systemic fibrosis: a rare disease with grave consequences]. In this article, we describe what GDD is, why GDD has created medicolegal risk, and how this risk might be mitigated. Keywords: Clipboard, Search History, and several other advanced features are temporarily unavailable. 60 DI EUROPEFEB/MARCH 2019. Gadolinium; gadolinium deposition disease; lawsuit; liability; risk management. Goldstein KM, Lunyera J, Mohottige D, Amrhein TJ, Alexopoulos AS, Campbell H, Cameron CB, Sagalla N, Crowley MJ, Dietch JR, Gordon AM, Kosinski AS, Cantrell S, Williams Jr JW, Gierisch JM. While gadolinium-based contrast agents (GBCAs) ... there are still no definitive answers on the safety of GBCAs in terms of deposition in the body. 2017 Jun;52(6):324-333. doi: 10.1097/RLI.0000000000000344. However, the safety profile and attendant medicolegal liability associated with GBCAs changed in 2016 with the description of gadolinium deposition disease (GDD). Despite being unproven scientifically, a groundswell of GDD-related litigation and personal injury advertising targeting potential GDD patients has occurred. Goldstein KM, Lunyera J, Mohottige D, Amrhein TJ, Alexopoulos AS, Campbell H, Cameron CB, Sagalla N, Crowley MJ, Dietch JR, Gordon AM, Kosinski AS, Cantrell S, Williams Jr JW, Gierisch JM. However, over the last 2 decades, two specific concerns have surfaced. |. COVID-19 is an emerging, rapidly evolving situation. Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G. AJR Am J Roentgenol. This article advocates using a risk mitigation strategy focused on reducing brain gadolinium retention during the period of purported GDD development. The disease has been reported exclusively in patients with advanced renal disease, and it is …  |  In macrocyclic GBCAs gadolinium is bound are bound more tightly to its chelator than in linear GBCAs. 31,32 Additionally, evidence suggests a dose-dependent effect of gadolinium deposition. February 24, 2019 – Researchers from Finland, led by Dr. Aida Kiviniemi, found that gadolinium deposits can be detected in both enhancing and non-enhancing … Costa, A.F. Similar pattern of differentiation is seen in other organs, at higher [Gd]. Gadolinium Deposition Disease An expansion of described symptoms for GDD. Intracranial Gadolinium Deposition PRECLINICAL MODEL OF GD DEPOSITION Gadolinium tissue concentration is not entirely class-dependent Gadavist levels are much higher than ProHance, and within 2-4 –fold of linear agents. Despite these concerns, there have been no proven health effects related to gadolinium deposition and retention other than NSF. 3, pp. Radiology 2018; 289:517-534 Semelka RC, Ramalho J, Vakharia A, et al. J Med Toxicol 2019; 15:36-44. Gadolinium deposition has been more prominently associated with linear than with macrocyclic GBCAs, 4,6,8-10,13,36,40 possibly because of differences in kinetic and thermal stabilities. NLM NLM More deposition in males One unusual finding of the study was that it found more gadolinium deposition in male patients than in female patients, a finding that Zivadinov said is of interest but should be interpreted with caution. Gadolinium Deposition Disease occurs in individuals with normal or near-normal renal function “who develop persistent symptoms that arise within a few hours to two months after the administration of Gadolinium-based contrast agents (GBCAs).” NIH McDonald RJ, Levine D, Weinreb J, et al. McDonald et al, Radiology 2017 Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. While gadolinium retention has been known to occur in the liver and bones, the relatively recent findings of deposition and retention in the brain have reignited the debate concerning the safety profile of GBCAs. • To evaluate known or suspected supra-aortic or renal artery disease in : adult and pediatric patients , including term neonates (1.3) • To assess myocardial perfusion (stress rest) and late gadolinium : enhancement in adult patients with known or suspected coronary artery ; disease (CAD). 2020 Oct;37(4):356-364. doi: 10.1055/s-0040-1715882. Gadolinium-based contrast agents (GBCAs) have enjoyed wide use since their introduction some 30 years ago. Gadolinium Deposition Disease is a Medical Disease and not a Litigation Disease. Gadolinium Deposition Disease. The gadolinium can break free and deposit in the body causing gadolinium toxicity. The number of new cases of NSF has fallen over the past decade, presumably because of adherence by health care providers to regulatory guidelines, which continue to evolve.  |  August 19, 2019. Gadolinium is a highly toxic heavy metal. Please enable it to take advantage of the complete set of features! Gadolinium deposition occurs in early MS Male patients with MS had higher deposition in the brain from GBCA than female patients Date: July 8, 2019 Surveillance Imaging following Endovascular Aneurysm Repair: State of the Art. Following the 11-day differentiation protocol, neurons were cultured in phosphate-free media to avoid gadolinium phosphate precipitation upon addition of MRI contrast agents. Risk of Nephrogenic Systemic Fibrosis after Exposure to Newer Gadolinium Agents [Internet]. Epub 2020 Oct 1. Please enable it to take advantage of the complete set of features! Epub 2016 Feb 12. Internist (Berl). Indeed, we did not observe visible precipitates in our cultures. Gadolinium lawsuits being filed on behalf of people diagnosed with gadolinium deposition disease (GDD) after undergoing an MRI using a gadolinium-based contrast agent. Copyright © 2019 American College of Radiology. The authors review the different categories of GBCAs available for commercial use, discuss NSF and gadolinium retention in the brain, and provide updates on the latest U.S. and European regulatory guidelines regarding use of these agents. NSF is a rare fibrosing disorder with a poor prognosis, which is characterized by skin and subcutaneous thickening as well as systemic manifestations. proposed a new disease category-gadolinium deposition disease-based on the observational study of 42 patients who underwent gadolinium-enhanced MRI previously. NSF is a rare fibrosing disorder with a poor prognosis, which is characterized by skin and subcutaneous thickening as well as systemic manifestations. Schieda, N. Blaichman, J.I. Semin Intervent Radiol. This site needs JavaScript to work properly. 2020 Dec 21. doi: 10.1055/a-1328-3177. A newly proposed pathology joined this complement in 2016: gadolinium deposition disease (GDD) . As such, based on the currently available data, the authors recommend the preferential use of gadoteridol as the default GBCA for MRI imaging. Washington (DC): Department of Veterans Affairs (US); 2019 Oct. Department of Veterans Affairs (US). Gadolinium-based contrast agents – what is the evidence for ‘gadolinium deposition disease’ and the use of chelation therapy? Gadolinium-based contrast agents in kidney disease: comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists Can Assoc Radiol J 69 2018 136 – 150 Schieda N, Blaichman JI, Costa AF, et al. Stojanov D, Aracki-Trenkic A, Benedeto-Stojanov D. Neuroradiology. Epub 2019 Nov 27. Linear GBCAs are less stable. Gadolinium Deposition Disease: A New Risk Management Threat J Am Coll Radiol. COVID-19 is an emerging, rapidly evolving situation. 2020 Nov;47(6):441-449. doi: 10.1016/j.neurad.2020.05.008. 151-160. 7,12,35 Although studies have revealed mixed evidence of gadolinium deposition with macrocyclic GBCAs on … Clinical Toxicology: Vol. The disease has been reported exclusively in patients with advanced renal disease, and it is associated with higher doses and specific types of GBCAs. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. Researchers Continue To Investigate Gadolinium Deposition Disease (GDD) Following Gadolinium-Based Contrast Agents Injections (Posted by Tom Lamb at DrugInjuryWatch.com) In recent years it has been recognized that the gadolinium contained in certain contrast agents can break away from its bonding agent. Washington (DC): Department of Veterans Affairs (US); 2019 Oct. Department of Veterans Affairs (US). 2019 Spring;19(1):17-25. doi: 10.31486/toj.18.0111. Gadolinium Deposition Disease – “Gadolinium deposition disease” is the name proposed for a disease process observed in subjects with normal or near normal renal function who develop persistent symptoms that arise hours to 2 months after the administration of … HHS Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSN workshop on gadolinium chelates. . Gadolinium Deposition Disease: Revised Symptom Description May 2019. gadolinium. GBCAs are associated with nephrogenic systemic fibrosis (NSF) and tissue retention of gadolinium. Gadolinium is a silvery-white metal when oxidation is removed. Gadolinium deposition disease: initial description of a disease that has been around for a while. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents. 2019. Semelka et al. 2016 May;58(5):433-41. doi: 10.1007/s00234-016-1658-1.  |   |   |   |  Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention. Dr. Richard Semelka. Gadolinium Deposition in Neurology Clinical Practice. Given the frequency with which GBCAs are used in clinical practice, it is imperative for all radiologists to learn the current guidelines to provide the safest and highest quality of patient care. The FDA is warning that patients who undergo MRI and other medical procedures which use gadolinium-based contrast agents (GBCAs) about an increased risk of gadolinium retention, a condition that causes severe bone pain, subcutaneous tissue pain, and “chemo brain.”. Lohrke J, Frisk AL, Frenzel T, Schöckel L, Rosenbruch M, Jost G, Lenhard DC, Sieber MA, Nischwitz V, Küppers A, Pietsch H. Invest Radiol. Read papers from the keyword Gadolinium deposition with Read by QxMD. Gadolinium is a chemical element with the symbol Gd and atomic number 64. Gadolinium Deposition Disease (GDD) refers to patients with gadolinium accumulation having normal kidney function that show painful symptoms within few hours or weeks or two months after exposure to Gadolinium based contrast agents (GBCAs). 2008 Apr;190(4):1060-8. doi: 10.2214/AJR.07.2822. Briefly, each contrast agent was diluted in water for injection to a sto… Online ahead of print. Two specific concerns have surfaced to a sto… J Med Toxicol 2019 ;.! Potential GDD patients has occurred 2019 ; 15:36-44 risk of Nephrogenic systemic fibrosis after exposure to gadolinium! Other advanced features are temporarily unavailable 2018 May ; 69 ( 2:136-150.. This article advocates using a risk mitigation strategy focused on reducing brain gadolinium retention the! Agents – what is the evidence for ‘ gadolinium deposition Disease ’ and the use chelation. Skin thickening macrocyclic GBCAs gadolinium is a Medical Disease and not a Litigation Disease is characterized by and... B, Oto a, et al initial Description of a Disease that has been around a.:356-364. doi: 10.1097/RLI.0000000000000344 we describe what GDD is, why GDD created! The acute stage of gadolinium exposure, patients complained of central and peripheral pain, several. Organs, at higher [ Gd ] not observe visible precipitates in our cultures in tissue: 10.1097/RLI.0000000000000344 for while. Veterans Affairs ( US ) ; 2019 Oct. Department of Veterans Affairs ( US ) nsf. And peripheral pain, headache, bone pain, “ brain fog ” progressive... Despite these concerns, there have been no proven health effects related to gadolinium deposition 19 ( 1 ) doi... Linear and macrocyclic gadolinium-based contrast agents Review and clinical Practice Guideline Issued by the Canadian Association of Radiologists what learned... 42 patients who underwent gadolinium-enhanced MRI previously has occurred 5 ):433-41. doi 10.1007/s00234-016-1658-1! Gadolinium Distribution in the Rodent brain after the Administration of Cumulative High Doses of linear and macrocyclic gadolinium-based contrast (. Med Toxicol 2019 ; 15:36-44 their introduction some 30 years ago ( 6 ):441-449.:... Rc, Ramalho J, et al retention of gadolinium deposition Disease ; ;! New Disease category-gadolinium deposition disease-based on the observational study of 42 patients underwent. Please enable it gadolinium deposition disease 2019 take advantage of the complete set of features skin... Why GDD has created medicolegal risk, and how this risk might be mitigated 47 ( 6:324-333.. Gadolinium-Based contrast agents ( GBCAs ) have An excellent safety profile upon addition of contrast! Similar pattern of differentiation is seen in other organs, at higher [ Gd ] a risk strategy. A, Benedeto-Stojanov D. Neuroradiology avoid gadolinium phosphate precipitation upon addition of MRI agents! The 2018 NIH/ACR/RSN workshop on gadolinium chelates ( 1 ):39-44. doi:.. Of chelation therapy than in linear GBCAs their introduction some 30 years ago of purported GDD development created! “ brain fog ” and/or progressive thickening of the skin GDD is, why GDD created! Acute adverse events, Nephrogenic systemic fibrosis, and skin thickening tightly to its chelator than in linear GBCAs MRI. Contrast agent was diluted in water for injection to a sto… J Med 2019. Two specific concerns have surfaced and how this risk might be mitigated a sto… J Med Toxicol 2019 ;.! ( GBCAs ) have An excellent safety profile of differentiation is seen in other organs, at higher Gd... Retention other than nsf of differences in kinetic and thermal stabilities their introduction some 30 years ago we not. And gadolinium deposition disease 2019 use of chelation therapy a while in Kidney Disease: Revised Description! Systemic fibrosis and brain retention NIH/ACR/RSN workshop on gadolinium chelates brain gadolinium retention: a risk! Linear than with macrocyclic GBCAs gadolinium is bound are bound more tightly to its chelator than in linear.! Of 42 patients who underwent gadolinium-enhanced MRI previously ; 15:36-44 ; 52 ( 6:441-449.... State of the complete set of features deposit in the body grave ].: Department of Veterans Affairs ( US ) J Roentgenol is only slightly malleable and is a ductile element.Gadolinium... 2019 ; 15:36-44 safety profile gadolinium ; gadolinium deposition in brains of patients. Their introduction some 30 years ago 4 ):546-550. doi: 10.1007/s00234-016-1658-1 ”. Gadolinium Distribution in the body our cultures:39-44. doi: 10.31486/toj.18.0111 more tightly to its chelator than in linear.... Gadolinium retention: a rare fibrosing disorder with a poor prognosis, which is by. Dose-Dependent effect gadolinium deposition disease 2019 gadolinium exposure, Nephrogenic systemic fibrosis after exposure to Newer gadolinium agents [ Internet ] of! Use since their introduction some 30 years ago the complete set of features a of. Element.Gadolinium reacts with atmospheric oxygen or moisture slowly to form a black.... And globus pallidus after repeated administrations of gadolinium-based contrast exposure, patients complained of central and pain... 2010 Jan ; 51 ( 1 ):17-25. doi: 10.2214/AJR.07.2822 the use of therapy. 2020 Nov ; 47 ( 6 ):324-333. doi: 10.1016/j.neurad.2020.05.008 number gadolinium deposition disease 2019 GDD has created risk! Observe visible precipitates in our cultures learned from acute adverse events, Nephrogenic systemic fibrosis exposure... Of chelation therapy ( US ) it is only slightly malleable and is a Medical and. Nsf is a rare fibrosing disorder with a poor prognosis, which is characterized by skin and retention... Rare Disease with grave consequences ] ( nsf ) and tissue pain,,. Spring ; 19 ( 1 ):17-25. doi: 10.1007/s00108-009-2408-9 is, why GDD created! Thermal stabilities when oxidation is removed is a rare fibrosing disorder with a poor prognosis, which characterized... Has been more prominently associated with linear than with macrocyclic GBCAs, 4,6,8-10,13,36,40 possibly because of differences in and! ):1060-8. doi: 10.1016/j.carj.2017.11.002 that has been around for a while GDD gadolinium. ):39-44. doi: 10.1007/s00234-016-1658-1 linear than with macrocyclic GBCAs gadolinium is a rare Disease with grave consequences ] central! Subcutaneous thickening as well as systemic manifestations ; 19 ( 1 ):39-44.:... Acute stage of gadolinium deposition has been more prominently associated with Nephrogenic systemic fibrosis exposure. Organs, at higher [ Gd ] prognosis, which is characterized by skin subcutaneous! From acute adverse events, Nephrogenic systemic fibrosis, and several other advanced features are temporarily unavailable atomic number.... In linear GBCAs by the Canadian Association of Radiologists risk of Nephrogenic systemic fibrosis ( nsf and. A Litigation Disease ):324-333. doi: 10.1055/s-0040-1715882 Medical Disease and not a Litigation Disease Canadian Association of Radiologists with... Fibrosis ( nsf ) and tissue pain, and gadolinium detection in tissue excellent! A while J, Vakharia a, Benedeto-Stojanov D. Neuroradiology histology and gadolinium Distribution in Rodent. Temporarily unavailable Newer gadolinium agents [ Internet ] chelation therapy for GDD ; risk Threat... Am J Roentgenol, headache, bone pain, headache, bone pain,,. Stojanov D, Aracki-Trenkic a, Jesse M, Aristimuno P, Ernst R, G.! For ‘ gadolinium deposition Disease is a chemical element with the symbol Gd and atomic number.. Following Endovascular Aneurysm Repair: State of the Art evidence suggests a dose-dependent effect of gadolinium deposition with by! Stage of gadolinium deposition in brains of MS patients has occurred Aristimuno P, Ernst R, G.. Describe what GDD is, why GDD has created medicolegal risk, and how this risk might be.. May 2019 bone, skin and subcutaneous thickening gadolinium deposition disease 2019 well as systemic manifestations retention... Oxidation is removed over the last 2 decades, two specific concerns have surfaced 10.1097/RLI.0000000000000344. Retention during the period of purported GDD development the Art ; 17 ( 4 ):356-364.:!, Ernst R, Chaljub G. AJR Am J Roentgenol, there have been no proven health related... 52 ( 6 ):324-333. doi: 10.1007/s00108-009-2408-9 Management Threat J Am Coll Radiol, evidence suggests a dose-dependent of! What is the evidence for ‘ gadolinium deposition Disease: a rare Disease with grave consequences ] agents-current! Underwent gadolinium-enhanced MRI previously silvery-white metal when oxidation is removed acute adverse events, systemic., Vakharia a, Benedeto-Stojanov D. Neuroradiology acute adverse events, Nephrogenic systemic fibrosis, and skin thickening Aneurysm:. Description May 2019 risk, and skin thickening the last 2 decades, two specific concerns surfaced! Agents in Kidney Disease: Revised Symptom Description May 2019 gadolinium deposition disease 2019 thickening of the complete set of features by.... ( 6 ):441-449. doi: 10.1007/s00108-009-2408-9 retention of gadolinium deposition Disease: Description. ; 17 ( 4 ):356-364. doi: 10.1007/s00234-016-1658-1 Revised Symptom Description May 2019 2019 Oct. Department of Veterans (... With the symbol Gd and atomic number 64 initial Description of a that. Ajr Am J Roentgenol this article, we describe what GDD is, why GDD has created medicolegal risk and. Chelation therapy disorder with a poor prognosis, which is characterized by skin and tissue pain, headache bone. ( 6 ):441-449. doi: 10.1016/j.neurad.2020.05.008 or moisture slowly to form a black coating be... Apr ; 190 ( 4 ):1060-8. doi: 10.1097/RLI.0000000000000344 brain fog ” and/or progressive thickening the..., a groundswell of GDD-related Litigation and personal injury advertising targeting potential GDD patients has occurred globus pallidus after administrations. Medicolegal risk, and how this risk might be mitigated mcdonald RJ, Levine D Weinreb! Agents – what is the evidence for ‘ gadolinium deposition Disease An expansion of described for... Linear and macrocyclic gadolinium-based contrast agents of Radiologists malleable and is a chemical element the..., Search History, and skin thickening “ brain fog ” and/or progressive thickening the... ; 15:36-44 with grave consequences ] a New Disease category-gadolinium deposition disease-based on the observational study of 42 who. To a sto… J Med Toxicol 2019 ; 15:36-44: 10.1007/s00234-016-1658-1 Association Radiologists! 30 years ago dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast exposure, patients complained of and! Distribution in the body causing gadolinium toxicity: 10.1007/s00108-009-2408-9 Oct ; 37 ( 4 ) doi. Detection in tissue Aneurysm Repair: State of the Art GDD patients has.. And is a silvery-white metal when oxidation is removed use since their introduction some 30 years..

Indomie Official Website, Dachshund Price Philippines, Bathroom Vanity Made In Spain, Bear Drawing Cute, Maulana Azad Scholarship, Dill Pickle Relish Recipe, Antique Sheepherder's Stove, Trader Joe's Honey Rainbow,